Delving into the Latest Updates on Abacavir Sulfate/Lamivudine/Zidovudine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Abacavir (as sulfate)/Lamivudine/Zidovudine, Abacavir/lamivudine/zidovudine, Abacavir/zidovudine/lamivudine

+ [8]

Target

RT

Action

inhibitors

Mechanism

RT inhibitors(Viral reverse transcriptase inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication-

Originator Organization

ViiV Healthcare Ltd.

Active Organization

ViiV Healthcare BVViiV Healthcare UK Ltd.

Inactive Organization

ViiV Healthcare Co.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (14 Nov 2000),

HIV Infections

RegulationAccelerated Approval (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC32H42N14O8S

InChIKeyYATVXQQJLKIPSI-SBGMWXOCSA-N

CAS Registry364057-50-1

Aicardi-Goutières syndrome (AGS) is a disease of children, particularly affecting the brain and the skin. There is a close link between AGS and increased amounts of a chemical called interferon. Normally humans only produce interferon when they are infected with a virus. In AGS, there is no viral infection. Instead, the cells in the cells of affected patients are confused into thinking that their own genetic material is coming from a virus. As a result they produce interferon all the time, which acts as a poison that damages the cells. The Investigators wish to treat AGS patients with drugs called reverse transcriptase inhibitors (RTIs), used to fight the HIV-1 virus that causes AIDS. The investigators will monitor the effect of treatment on interferon levels, and look at other markers which might give us clues to how the drugs are working. The trial is funded by the Medical Research Council, and involves experts based in Edinburgh, Birmingham, Manchester and Great Ormond Street Hospital.

Start Date24 Aug 2022

Sponsor / Collaborator

The University of Edinburgh

[+2]

NCT01352715

/ CompletedPhase 3IIT

Multicenter Study of Options for Second-Line Effective Combination Therapy (SELECT)

The study was conducted on people who were taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), a type of anti-HIV drug) but the drugs in this regimen were not doing a good job of fighting their HIV infection.
The main purpose of this study was to compare two other anti-HIV drug regimens to see how well they fight HIV. The study also looked at how well participants tolerate the drug regimens and how safe they are.
The study was designed to determine whether taking the combination of lopinavir/ritonavir (LPV/r) plus raltegravir (RAL) works as well as what is usually used for second-line therapy: LPV/r plus the best-available nucleoside (nucleotide) reverse transcriptase inhibitor (NRTI) combination. Testing a regimen that does not include any NRTIs was important because NRTIs may no longer work for patients who received them as part of their first treatment regimen.

Start Date13 Mar 2012

Sponsor / Collaborator

National Institute of Allergy & Infectious Diseases

NCT00865475

/ CompletedPhase 4IIT

A Randomized Comparative Clinical Trial of ZDV + 3TC + ABC (Trizivir) vs Monotherapy With Lopinavir/R (Kaletra) in Patients With Viral Suppression on Previous Treatment With ZDV + 3TC + ABC (Trizivir) for Preventing Lipoatrophy

The aim of this study is to measure the prevention of lipoatrophy in patients treated with Lopinavir/R in monotherapy versus ZDV + 3TC + ABC

Start Date01 Dec 2008

Sponsor / Collaborator

SEIMC-GESIDA Foundation

[+1]

100 Clinical Results associated with Abacavir Sulfate/Lamivudine/Zidovudine

Login to view more data

100 Translational Medicine associated with Abacavir Sulfate/Lamivudine/Zidovudine

Login to view more data

100 Patents (Medical) associated with Abacavir Sulfate/Lamivudine/Zidovudine

Login to view more data

95

Literatures (Medical) associated with Abacavir Sulfate/Lamivudine/Zidovudine

01 Nov 2022·RADIATION PHYSICS AND CHEMISTRY

Evaluation of photon interaction parameters of Anti-HIV drugs

Author: Akbaba, Ugur ; Abu Al-Sayyed, Mohammed Ibrahim ; Alim, Bunyamin ; Sakar, Erdem ; Ozpolat, Ozgur Firat

Medical treatment inevitably exposes individuals to radiation, including those taking drugs used to treat and prevent human immunodeficiency virus (HIV).Motivated by this, we investigated the radiation interaction properties of several HIV drugs to determine the interaction parameters, mass attenuation coefficient (MAC), at. cross section (ACS), electronic cross section (ECS), effective at. numbers (Zeff), and effective electron d. (Neff).We calculated the values using the Phy-X/PSD software in the range of 0.015-15 MeV.Addnl., we calculated the exposure build-up factor (EBF), and energy absorption build-up factor (EABF) values of the drugs up to 40 mean free path (MFP) using the geometric progression (G-P) method.From our findings, we determined that Combivir, with its relatively high heavy element content, had the highest radiation attenuation capacity, whereas the probability of Lopinavir interacting with photons was the lowest compared with the other drugs.The results of the EBF and EABF parameters, including the scattering effects, ordered the drugs opposite to the primary interaction parameters such as MAC, ACS, ECS, and Zeff.These findings can guide the treatment process of HIV-pos. patients and inform HIV prevention practices conducted alongside radiotherapy, as the interaction between radiation and a drug may cause deterioration in the drug's structure.

01 May 2016·Medizinische Klinik, Intensivmedizin und NotfallmedizinQ4 · MEDICINE

Life-threatening cardiac arrhythmias due to drug-induced QT prolongation

Q4 · MEDICINE

Article

Author: Pfister, R ; Michels, G ; Kochanek, M

BACKGROUND:

Long QT syndrome (LQTS) can lead to ventricular arrhythmia, especially torsade de pointes (TdP) tachycardia and/or ventricular tachycardia (VT). The aim of this study is to characterize patients with life-threatening cardiac arrhythmias associated with drug-induced LQTS and to identify risk factors of distinct presenting arrhythmias.

MATERIAL AND METHODS:

In this retrospective study, we present 33 consecutive cases of life-threatening cardiac arrhythmias associated with drug-induced long QT, which were direct admitted as emergency to a medical intensive care unit (MICU) during an observational time of 6 years.

RESULTS:

Of 33 identified cases, 55 % presented with TdP with the need of resuscitation and 45 % showed nonsustained VT, respectively. In the total cohort the mean corrected QT interval (QTc) was 532 ± 29 ms, with 530 ± 31 ms (n = 14) in men and 533 ± 28 ms (n = 19) in women (p = 0.80), respectively. Cardiac drugs with QTc interval prolonging effect were reported in 24 % of cases, and the other 76 % involved noncardiac medications. Although hypokalemia is the most common risk factor for drug-induced malignant arrhythmias, a QTc interval of at least 500 ms seems to be the major determinant of the risk of drug-induced proarrhythmias. Interestingly, patients with TdP exhibit more bradycardia as such with VT.

CONCLUSIONS:

This is the first study of patients with drug-induced life-threatening cardiac arrhythmias who were admitted as a case of emergency to a MICU. Physicians should be aware of drug-induced LQTS and be able to identify patients at risk and avoid specific drugs in such patients.

01 Feb 2016·Proteomics. Clinical applicationsQ3 · BIOLOGY

¹⁸O proteomics reveal increased human apolipoprotein CIII in Hispanic HIV‐1+ women with HAART that use cocaine

Q3 · BIOLOGY

Article

Author: Suárez, Erick ; Jorge, Inmaculada ; Zenón, Frances ; Segarra, Annabell C. ; Vázquez, Jesús ; Meléndez, Loyda M. ; Serrano, Horacio ; Cruz, Ailed

Purpose:

Drug abuse is a major risk factor in the development and progression of HIV‐1. This study defines the alterations in the plasma proteome of HIV‐1‐infected women that use cocaine.

Experimental design:

Plasma samples from 12 HIV‐seropositive Hispanic women under antiretroviral therapy were selected for this study. Six sample pairs were matched between nondrug users and cocaine users. After IgG and albumin depletion, SDS‐PAGE, and in‐gel digestion, peptides from nondrug users and cocaine users were labeled with 16O and 18O, respectively, and subjected to LC‐MS/MS and quantitation using Proteome Discover and QuiXoT softwares and validated by ELISA.

Results:

A total of 1015 proteins were identified at 1% false discovery rates (FDR). Statistical analyses revealed 13 proteins with significant changes between the two groups, cocaine and noncocaine users (p < 0.05). The great majority pertained to protection defense function and the rest pertained to transport, homeostatic, regulation, and binding of ligands. Apolipoprotein CIII was increased in plasma of HIV+ Hispanic women positive for cocaine compared to HIV+ nondrug users (p ≤ 0.05).

Conclusions and clinical relevance:

Increased human apolipoprotein CIII warrants that these patients be carefully monitored to avoid the increased risk of cardiovascular events associated with HIV, HAART, and cocaine use.

100 Deals associated with Abacavir Sulfate/Lamivudine/Zidovudine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Abacavir Sulfate/Lamivudine/Zidovudine	J05AR04	-

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	14 Nov 2000

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00084149 (CTgov)	Phase 2	HIV Infections	54	Cyclosporine (Cyclosporine)	xxhrrxwhgk(flpjnhffgm) = rabomifpip dvpszkczte (hpaohertko, swuxgqcimm - dnhsomfmzd) View more	-	13 Sep 2018
				Cyclosporine (No Cyclosporine)	xxhrrxwhgk(flpjnhffgm) = sqpetzkmkn dvpszkczte (hpaohertko, gszfmlilwh - cxtpbkahwe) View more
NCT00270296 (CTgov)	Phase 2	HIV Infections	730	Lamivudine/Zidovudine+Lopinavir/Ritonavir	mdboxtontd = njwxjqdktf tdkigzrohk (vzssujtili, nqqqksmwwq - qohlafnnty) View more	-	05 Jun 2017
NCT01352715 (A5273 \| SELECT, CTgov)	Phase 3	HIV Infections	515	Lopinavir/ritonavir+raltegravir (Arm A: LPV/r Plus RAL)	vwrpdusazw = ouvhgcvsny ylpdwskrmd (iqjfmdcjjy, yxlfzbrynm - sahdegcmih) View more	-	06 Jan 2016
				Abacavir/lamivudine+Zidovudine+Abacavir+Lamivudine/zidovudine+Abacavir/lamivudine/zidovudine+Emtricitabine/tenofovir disoproxil fumarate+Lamivudine+Lopinavir/ritonavir (Arm B: LPV/r Plus Best Available NRTIs)	vwrpdusazw = dagfqooyqi ylpdwskrmd (iqjfmdcjjy, foatapxvnc - smdxftzvrz) View more
NCT00851630 (THIRST, CTgov)	Phase 4	Tuberculosis \| HIV Infections \| Immune Reconstitution Inflammatory Syndrome	70	Fixed dose combination zidovudine/lamivudine/abacavir (Early)	mfvwpmegwh = cvmxfhygss jvctynunon (jggkgxzhdd, dbdftfevhk - xozvajksiw) View more	-	08 Jan 2010
				Fixed dose combination zidovudine/lamivudine/abacavir (Delayed)	mfvwpmegwh = jabdbsiwcc jvctynunon (jggkgxzhdd, jilguoiytv - lqvgymltzd) View more
IAS2010	Not Applicable	AIDS-related Kaposi Sarcoma	23	Co-formulated abacavir/lamivudine/zidovudine	pzqkxeajdj(pnpmwgjmqf) = gbbaikgiqi emkrurgclz (brfesrgomh )	-	01 Jan 2010
				Co-formulated abacavir/lamivudine plus co-formulated lopinavir/ritonavir	pzqkxeajdj(pnpmwgjmqf) = fxfqgpumcb emkrurgclz (brfesrgomh )
DART trial (IAS2009)	Not Applicable	-	600	Combivir plus abacavir	btzlkodjmk(dwybacehca) = aqsnnlunto netcbeovoe (xbzjrtahsv )	Negative	01 Jan 2009
				Combivir plus nevirapine	btzlkodjmk(dwybacehca) = kwhizmfriq netcbeovoe (xbzjrtahsv )
IAS2007	Not Applicable	HIV Infections	54	Trizivir (TZV) plus tenofovir (TDF)	kdlzodtzpg(hatwsihzfx) = uhfdaobpav hovxqmviqt (caxqiyqbjz ) View more	-	01 Jan 2007
IAS2006	Not Applicable	Maintenance	23	Trizivir/Kaletra	tpiomlfkpf(hbidhjmwwr) = Drug-related AEs occurred in 13/23 subjects, with gastrointestinal disorders the most common (10/23) uopugxyvgq (cjjdxvuuvi ) View more	-	01 Jan 2006
				Trizivir
IAS2006	Not Applicable	HIV Infections	155	Trizivir-containing combination of antiretrovirals	lbkiqzyogg(cnitajjnro) = nqoadthdto nhptubqkib (ljirreuuhz, 99 - 370) View more	-	01 Jan 2006
IAS2005	Not Applicable	-	51	Trizivir (TZV) + Tenofovir (TDF)	pcppicpkpf(zlgdkbbkuk) = AEs leading to discontinuation were nausea, fatigue, and cancer junhcpdhsq (hplwnxwcuk )	-	01 Jan 2005